|
1.
|
2024/08/08
|
|
Serum Cytokeratin 18 Fragment is an Indicator for Treating Metabolic Dysfunction associated Steatotic Liver Disease
|
|
2.
|
2024/07/25
|
|
Identification of risk groups for advanced liver fibrosis in the general population using the Fibrosis-3 index
|
|
3.
|
2024/07/01
|
|
Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction–Associated Steatotic Liver Disease
|
|
4.
|
2024/06/01
|
|
Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan
|
|
5.
|
2024/04/25
|
|
Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease
|
|
6.
|
2024/04/09
|
|
Different Food Preferences in Patients with Gastrointestinal Disorders
|
|
7.
|
2024/04/01
|
|
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
|
|
8.
|
2024/04/01
|
|
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
|
|
9.
|
2023/12/01
|
|
Impact of fibrosis on liver-related event incidence in nonalcoholic fatty liver disease: A multicenter observational study.
|
|
10.
|
2023/12/01
|
|
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study.
|
|
11.
|
2023/10/01
|
|
Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
|
|
12.
|
2023/10/01
|
|
The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study
|
|
13.
|
2023/09/01
|
|
Lean nonalcoholic fatty liver disease: Age-dependent differences in pathology, prognosis, and liver-related events
|
|
14.
|
2023/08/17
|
|
Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease.
|
|
15.
|
2023/08/12
|
|
Brain activity in response to food images in patients with irritable bowel syndrome and functional dyspepsia
|
|
16.
|
2023/08/02
|
|
A Case of Idiopathic Peptic Ulcer Disease Treated Effectively with Trimebutine Maleat
|
|
17.
|
2023/06/19
|
|
Efficacy of endoscopic ultrasound-guided abscess drainage for non-pancreatic abscesses: A retrospective study.
|
|
18.
|
2023/06/01
|
|
Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study
|
|
19.
|
2023/06/01
|
|
Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease
|
|
20.
|
2023/05/10
|
|
Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
|
|
21.
|
2023/05/01
|
|
Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease
|
|
22.
|
2023/04/22
|
|
Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
|
|
23.
|
2023/04/01
|
|
Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study
|
|
24.
|
2023/04/01
|
|
Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients
|
|
25.
|
2023/02/01
|
|
Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study
|
|
26.
|
2023/02/01
|
|
SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
|
|
27.
|
2022/12
|
|
Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan
|
|
28.
|
2022/10/05
|
|
Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia
|
|
29.
|
2022/07/18
|
|
Fibrosis-3 index: A new score to predict liver fibrosis in patients with Nonalcoholic Fatty Liver Disease without age as a factor
|
|
30.
|
2022/07/01
|
|
Association of serum and fecal bile acid patterns with liver fibrosis in biopsy-proven nonalcoholic fatty liver disease: An observational study
|
|
31.
|
2022/04/12
|
|
Efficacy of primary drainage by endoscopic ultrasound-guided biliary drainage for unresectable pancreatic adenocarcinoma
|
|
32.
|
2022/04/06
|
|
Treatment of ectopic variceal bleeding at choledochojejunostomy by endoscopic glue injection therapy with cyanoacrylate: Report of three cases including long-term outcomes
|
|
33.
|
2022/03
|
|
Afferent-Loop Syndrome Treated with Endoscopic Ultrasound-Guided Drainage of the Afferent Loop with a Plastic Stent
|
|
34.
|
2022/01/17
|
|
Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A
Multicenter Registry-Based Cohort Study
|
|
35.
|
2022/01
|
|
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
|
|
36.
|
2022
|
|
Portal Hypertensive Gastropathy in Liver Cirrhosis: Prevalence, Natural History, and Risk Factors
|
|
37.
|
2021/11/21
|
|
Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
|
|
38.
|
2021/11/01
|
|
Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease
|
|
39.
|
2021/08
|
|
Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease
|
|
40.
|
2021/05/27
|
|
Combination of type Ⅳ collagen 7S, albumin concentration, and platelet count predicts prognosis of non-alcoholic fatty liver disease
|
|
41.
|
2021/05/03
|
|
Primary Epstein-Barr virus infection shortly after primary Cytomegalovirus infection: a case report
|
|
42.
|
2021/05/01
|
|
Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years.
|
|
43.
|
2021/05
|
|
Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis.
|
|
44.
|
2021/04/01
|
|
Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis-A Case Suggesting the "Gastrin Link Theory".
|
|
45.
|
2021/04
|
|
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040
|
|
46.
|
2021/03
|
|
Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan
|
|
47.
|
2021/02/18
|
|
Disappearance of Gastric Hyperplastic Polyps after the Discontinuation of Proton Pump Inhibitor in a Patient with Liver Cirrhosis
|
|
48.
|
2021/02/14
|
|
FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic.
|
|
49.
|
2020/12/19
|
|
Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study.
|
|
50.
|
2020/09/04
|
|
Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals:A Cross-Sectional Study
|
|
51.
|
2020/03/11
|
|
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
|
|
52.
|
2020/02/27
|
|
Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty lever disease.
|
|
53.
|
2020
|
|
Efficacy and safety of temporary biliary stent for prevention of post-ERCP cholangitis after endoscopic common bile duct stone removal :a retrospective study
|
|
54.
|
2019/10/15
|
|
High Prevalence of Autoimmune Gastritis in Patients with Nonalcoholic Steatohepatitis
|
|
55.
|
2019/09/27
|
|
Four cases of gastric cancer in patients with autoimmune gastritis
|
|
56.
|
2019/09
|
|
Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
|
|
57.
|
2019/08
|
|
Infection phase is a predictor of pruritus in patients with hepatitis B virus infection
|
|
58.
|
2019/03
|
|
Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease
|
|
59.
|
2018/10
|
|
Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease.
|
|
60.
|
2018/08
|
|
Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study.
|
|
61.
|
2018/07
|
|
A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD.
|
|
62.
|
2018/06
|
|
Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
|
|
63.
|
2018/06
|
|
Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
|
|
64.
|
2018/02
|
|
Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
|
|
65.
|
2018/02
|
|
Prevalence of pruritus in patients with chronic liver disease: A multicenter study.
|
|
66.
|
2018/01
|
|
Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.
|
|
67.
|
2017/11/27
|
|
Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease
|
|
68.
|
2017/10
|
|
A Novel Prognostic Algorithm for Patients with NAFLD-related Hepatocellular Carcinoma:A Nationwide Data-mining Analysis by Japan Study Group of NAFLD
|
|
69.
|
2017/10
|
|
Effective Biomarkers for advance fibrosis NASH and reflect biomarkers as changes of liver fibrosis with NASH
|
|
70.
|
2017/10
|
|
Prediction of hepatocellular carcinoma following direct-acting antiviral treatment for chronic hepatitis C
|
|
71.
|
2017/10
|
|
Risk prediction for the development and progression of nonalcoholic fatty liver disease with genetic markers
|
|
72.
|
2017/10
|
|
Sequential PEG-IFNa-2a and TDF+PEG-IFNa-2a combination therapy after long-term nucleic acid analog treatment effectively reduce hepatitis B surface antigten levels
|
|
73.
|
2017/04
|
|
Case report of diet-related improvements of non-alcoholic steatohepatitis evaluated by four consecutive liver biopsies
|
|
74.
|
2016/11
|
|
The association with non-alcoholic steatohepatitis and autoimmune gastritis-Coincidence or true nature?
|
|
75.
|
2016/10
|
|
Elevated WFAM2BP, ALT flare and HBs decline>1.0Log/ml during Peg IFN were predict drug free and HBs antigen clearance in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients
|
|
76.
|
2016/10
|
|
The level of the macrophage activation marker soluble CD163 is apredictor of fibrosis progression and inflammation in non-alcoholic steatohepatitis(NASH)
|
|
77.
|
2016/10
|
|
The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic response with chronic hepatitis C patients
|
|
78.
|
2016/06
|
|
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey
|
|
79.
|
2015/10
|
|
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease:multicenter survey
|
|
80.
|
2015/06
|
|
Copper Accumulates in Hemosiderins in Livers of Patients with Iron Overload Syndromes
|
|
81.
|
2015
|
|
Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease
|
|
82.
|
2015
|
|
Elevated Serum Levels of M2BPGI Predict the Burned Out NASH and Hepatocellular Carcinoma with Non-Alcoholic Steatohepatitis
|
|
83.
|
2015
|
|
Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
|
|
84.
|
2014/11
|
|
Effect of achieving drug-free status and HBs antigen decline in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients.
|
|
85.
|
2014/11
|
|
WFA-M2BP levels are usefull indicators of progression and improvement for monitoring liver fibrosis in patients with nonalcoholic steatohepatitis/ nonalcoholic fatty liver disease.
|
|
86.
|
2014/04
|
|
Prevalence and outcomes of acute hepatitis B in Okayama,Japan,2006-2010.
|
|
87.
|
2014/03
|
|
Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy.
|
|
88.
|
2013/07
|
|
Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis
|
|
89.
|
2013/04
|
|
Diagnostic Criteria for NAFLD/NASH
|
|
90.
|
2013/03
|
|
Treatment of nonalcoholic steatohepatitis with vitamins E and C:a pilot study
|
|
91.
|
2012/09
|
|
A prospective study showing poor prognosis in Japanese NASH patients with fibrosis stage F3-4
|
|
92.
|
2012/08
|
|
Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma
|
|
93.
|
2012/06
|
|
Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.
|
|
94.
|
2012/04
|
|
Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
|
|
95.
|
2011/05
|
|
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma.
|
|
96.
|
2009/07
|
|
Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis.
|
|
97.
|
2009/07
|
|
Wilson's disease masquerading as nonalcoholic steatohepatitis.
|
|
98.
|
2008/04
|
|
An analysis of risk factors for developing Hepatocellular carcinoma in a group of Hepatitis C patients with stage 3 fibrosis following interferon therapy.
|
|
99.
|
2005/04
|
|
Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.
|
|
100.
|
2004/05
|
|
Control of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study.
|
|
101.
|
2004/02
|
|
Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C.
|
|
102.
|
2003/07
|
|
Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C.
|
|
103.
|
2003/06
|
|
AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis.
|
|
104.
|
2002/12
|
|
Clinical significance of intrahepatic interleukin-8 in chronic hepatitis C patients.
|
|
105.
|
2002/11
|
|
Long term follow-up of a group of chronic hepatitis C patients treated with anti-inflammatory drugs following initial interferon therapy.
|
|
Display 5 items
|
|
Display all(105)
|
